Anzeige
Meldung des Tages: Der Vorteil des Meeresbodens: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Bavarian Nordic News

Aktie
WKN:  917165 ISIN:  DK0015998017 US-Symbol:  BVNKF Branche:  Biotechnologie Land:  Dänemark
26,68 €
+0,13 €
+0,49%
17.04.26
Depot/Watchlist
Marktkapitalisierung *
1,97 Mrd. €
Streubesitz
70,67%
KGV
15,06
Nachhaltigkeits-Score
70 %
Index-Zuordnung
-

Bavarian Nordic News

31.07.25 - GlobeNewswire
Bavarian Nordic Announces Closing of Sale of Priority Review Voucher and Upgrades its 2025 Financial Guidance
COPENHAGEN, Denmark, July 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the sale of its Priority Review Voucher (PRV). Upon completion, the ...
28.07.25 - dpa-AFX
AKTIE IM FOKUS: Evotec legen weiter zu - Positives Umfeld, Bavarian Nordic
FRANKFURT/KOPENHAGEN (dpa-AFX Broker) - Die Aktien von Evotec haben am Montag auf dem höchsten Stand seit Mitte Juni von positiven Nachrichten für die Branche profitiert. ...
28.07.25 - GlobeNewswire
Consortium Led by Nordic Capital and Permira Will Make All-Cash Recommended Purchase Offer for Bavarian Nordic
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF ...
24.07.25 - GlobeNewswire
Rumours of a Potential Takeover Offer for Bavarian Nordic A/S
COPENHAGEN, Denmark, July 24, 2025 – Bavarian Nordic A/S (OMX: BAVA) has become aware of market rumours regarding a potential takeover offer for Bavarian Nordic A/S by a ...
22.07.25 - GlobeNewswire
Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine
COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of ...
09.07.25 - GlobeNewswire
Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with European Country
Recurring order from an undisclosed European country to strengthen public preparedness. Combined with other recent orders from non-​European countries, the Company has now ...
26.06.25 - GlobeNewswire
Bavarian Nordic Announces the Initiation of Clinical Trials of Mpox Vaccine in Infants and Pregnant Women
First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women. The multi-​partner research project is aimed at expanding access to mpox ...
18.06.25 - GlobeNewswire
Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million
COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total ...
12.06.25 - GlobeNewswire
Bavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in Children
First children vaccinated in clinical study seeking to expand the target population for the chikungunya vaccine. COPENHAGEN, Denmark, June 12, 2025 – Bavarian Nordic A/S (OMX ...
09.05.25 - GlobeNewswire
Bavarian Nordic Announces Interim Results for the First Three Months of 2025
COPENHAGEN, Denmark , May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. ...
06.05.25 - GlobeNewswire
Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox Vaccines
Exercised options total USD 143.6 million Secures manufacturing and supply of freeze-​dried JYNNEOS ® to the U.S. in 2026 COPENHAGEN, Denmark, May 6, 2025 – Bavarian ...
02.05.25 - GlobeNewswire
Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom
COPENHAGEN, Denmark, May 2, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted ...
16.09.24 - ARIVA.DE Redaktion
WHO erteilt grünes Licht für Mpox-Impfstoff von Bavarian Nordic
Die Weltgesundheitsorganisation (WHO) hat den Mpox-​Impfstoff von Bavarian Nordic, MVA-BN, für den weltweiten Einsatz präqualifiziert. Dies ermöglicht den Vereinten Nationen ...

Newssuche

Videos

newspaper
16.04.26 +2,80%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »